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Introduction
New antibiotics have been introduced over the years to
overcome drug resistance, but even these antibiotics have
lost their efficacy against important Gram-negative bacteria
with resistance to these drugs increasing rapidly across
Europe and adjacent regions. We surveyed 800 hospital-
based physicians in 4 European countries and Russia to
assess their level of ARGN awareness and perceived ability
to manage this growing and serious problem.
Objectives
· Assess hospital-based physician awareness about man-
agement of ARGN infections
· Determine factors influencing physician awareness of
ARGN infections
· Identify opportunities to improve the diagnosis and
management of ARGN infections
Methods
We selected 800 hospital-based physicians from an
online panel of 7,700 physicians who reside in Italy,
Spain, France, Germany, or Russia, and who all have
recent experience in the treatment of patients with
Gram-negative bacterial infections. They answered ques-
tions through a secured, online web-based survey system.
We used a multivariate analysis to identify factors inde-
pendently affecting physician awareness of how best to
manage ARGN infections.
Results
Of participating physicians, 55% are in academic/university
hospitals while 38% are in community hospitals. About
45% have practiced >15 years, and the same proportion
reported treating >5 patients with ARGN infections in the
prior month. Less than a third of respondents felt either
very or extremely aware of how best to treat patients with
ARGN infections, yet 64% believe their colleagues are
aware of best practices and 75% believe their hospitals are
prepared to treat these infections. Only half of the respon-
dents believe guidelines exist in their hospitals for treating
ARGNs and about half believe rapid molecular diagnostic
tests are available to them. While 75% report using clinical
decision support tools generally, most do not have access
to a specific tool to predict those at high risk for ARGN
infections; 86% said they consider such a tool necessary.
More years in practice, recent experience treating a high
volume of ARGN infections, availability of local treatment
guidelines, specialization in infectious diseases, and practi-
cing in academic and university treatment centers were
independently associated with greater physician awareness.
Conclusions
A high proportion of hospital-based physicians in the 5
countries covered by the survey consider themselves una-
ware of the best ways to manage ARGN infections. Various
factors affect the degree of their awareness, but in general,
they indicate a need for more support specifically through
enhanced availability of guidelines, rapid molecular tests,
prediction tools, and effective antibiotics.
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